How are energy investors positioned?
BOSTON - Ginkgo Bioworks (NYSE:DNA), a biotech company whose stock has surged over 54% in the past year according to InvestingPro data, announced Wednesday a new strategic partnership with Inductive Bio and Tangible Scientific aimed at making AI-driven lab-in-the-loop drug discovery more accessible across the pharmaceutical industry.
The collaboration integrates Ginkgo Datapoints’ ADME profiling capabilities, Inductive Bio’s model-driven chemistry design platform, and Tangible Scientific’s compound management system to create a streamlined workflow for drug development. With a healthy current ratio of 5.41 and revenue growth of 25.21% over the last twelve months, Ginkgo appears well-positioned to support this expansion despite currently operating at a loss.
The partnership addresses fragmentation in the drug discovery process, which currently involves moving compounds across multiple vendors and locations, creating delays and coordination challenges. By connecting these three capabilities, the companies aim to accelerate the process from in-silico compound designs to validated experimental results.
"By tightly coupling model-driven design with streamlined logistics to deliver AI/ML-ready assay data in real-time, we’re making it easier for scientists to iterate quickly," said John Androsavich, General Manager at Ginkgo Datapoints.
The integrated service leverages Ginkgo’s ADME profiling, which provides measurements of microsomal stability, kinetic solubility, P450 inhibition, and permeability. Tangible Scientific, located near Boston’s biopharma hub, manages the storage and movement of compounds, while Inductive Bio’s Compass platform allows chemists to explore design ideas using fine-tuned prediction models.
This collaboration aligns with FDA initiatives for faster development timelines, increased use of AI tools, and adoption of non-animal approaches in preclinical testing, according to the press release statement.
The services are currently available for pharmaceutical and biotech teams looking to improve ADMET optimization and reduce iteration times across their development programs. For investors seeking deeper insights into Ginkgo’s financial health and growth prospects, InvestingPro offers comprehensive analysis including 12 additional ProTips and detailed valuation metrics in their Pro Research Report, available exclusively to subscribers.
In other recent news, Ginkgo Bioworks reported second-quarter revenue of $50 million, surpassing consensus estimates of $42 million. This revenue beat was attributed to strong cell engineering performance, despite a 12% year-over-year decline and a 48% drop in biosecurity revenue due to delays in international contracts. Additionally, Ginkgo Bioworks secured a $4.66 million contract to deliver an automated anaerobic phenotyping platform to the Environmental Molecular Sciences Laboratory at Pacific Northwest National Laboratory. The system will utilize Ginkgo’s Reconfigurable Automation Cart technology to enhance laboratory efficiency and data quality. In analyst updates, TD Cowen raised its price target for Ginkgo Bioworks from $12 to $16, maintaining a Buy rating on the stock. Furthermore, the company launched a new high-throughput ADME profiling service aimed at accelerating small molecule drug discovery. This service is designed to provide competitive pricing while performing all work domestically. Lastly, Ginkgo Bioworks appointed Brian O’Sullivan as the Head of Commercial for its Ginkgo Automation division.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.